Onesource Specialty Pharma
Market cap ₹17,201 Cr
- P/E
- 19.87
- Day range
- ₹1,433.60 – ₹1,542.20
- 52-week range
- ₹1,057.00 – ₹1,925.00
- Volume
- 6.08 L
- Open
- ₹1,516.00
- Prev close
- ₹1,521.60
Latest results · Q1 FY27(consolidated)Revenue ₹449 Cr+37.2%Profit ₹25 CrMargin 5.6%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
ONESOURCE in NSE indices and F&O
Research profile
Derived metrics
- Earn. yield
- 5.0%
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 44 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹432.1K Cr | 35.71 | 5.18 | 14.8% | 21.0% | 29.0% | 0.06 | +10.5% |
| Divi's LaboratoriesDIVISLAB | ₹245.5K Cr | 83.82 | 14.66 | 16.2% | 22.0% | 41.0% | 0.00 | +27.8% |
| Torrent PharmaTORNTPHARM | ₹181.3K Cr | 76.11 | 19.22 | 26.8% | 15.0% | 34.0% | 1.79 | +54.8% |
| Apollo HospitalsAPOLLOHOSP | ₹116.9K Cr | 56.14 | 13.60 | 22.6% | 17.0% | 16.0% | 0.90 | +20.6% |
| Zydus LifesciencesZYDUSLIFE | ₹114.3K Cr | 25.57 | 4.26 | 20.1% | 21.0% | 24.0% | 0.46 | +22.0% |
| CiplaCIPLA | ₹108.6K Cr | 32.26 | 3.20 | 11.8% | 15.0% | 17.0% | 0.02 | +2.3% |
| Laurus LabsLAURUSLABS | ₹107.2K Cr | 98.02 | 20.20 | 18.2% | 18.0% | 32.0% | 0.48 | +29.0% |
| Onesource Specialty PharmaONESOURCE | ₹17.2K Cr | 19.87 | — | — | — | — | — | — |
| Sector median | ₹45.8K Cr | 49.95 | 5.80 | 14.6% | 16.0% | 22.5% | 0.31 | +17.1% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Quarterly results
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|---|
| Revenue | ₹449.02 Cr | ₹428.22 Cr | ₹290.34 Cr | ₹375.76 Cr | ₹327.27 Cr | ₹425.95 Cr |
| Other income | ₹3.80 Cr | ₹2.09 Cr | ₹4.63 Cr | ₹3.04 Cr | ₹5.27 Cr | ₹2.89 Cr |
| Total income | ₹452.83 Cr | ₹430.31 Cr | ₹294.97 Cr | ₹378.80 Cr | ₹332.54 Cr | ₹428.84 Cr |
| Total expenses | ₹428.23 Cr | ₹430.64 Cr | ₹380.89 Cr | ₹373.06 Cr | ₹334.07 Cr | ₹345.34 Cr |
| Profit before tax | ₹20.29 Cr | -₹29.20 L | -₹93.01 Cr | ₹5.74 Cr | -₹4.40 Cr | ₹83.50 Cr |
| Profit after tax | ₹25.00 Cr | ₹4.60 Cr | -₹88.70 Cr | ₹10.49 Cr | -₹18.60 L | ₹98.20 Cr |
| Basic EPS | ₹2.18 | ₹0.40 | ₹-7.74 | ₹0.92 | ₹-0.02 | ₹8.61 |
| Diluted EPS | ₹2.18 | ₹0.40 | ₹-7.74 | ₹0.91 | ₹-0.02 | ₹8.59 |
| Debt to equity | Not available — not reported in this filing | Not available — not reported in this filing | Not available — not reported in this filing | Not available — not reported in this filing | 0.00 | 0.00 |
| Debt service coverage | Not available — not reported in this filing | Not available — not reported in this filing | Not available — not reported in this filing | Not available — not reported in this filing | Not available — not reported in this filing | 0.02 |
This company files both consolidated and standalone results. Consolidated figures are shown; the two are never combined.
Corporate actions
Sourced from the company's NSE XBRL filing dated 25 Jul 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Onesource Specialty Pharma: common questions
Answered from the figures on this page.
